1. Bacillus thuringiensis: From biopesticides to anticancer agents.
- Author
-
Santos EN, Menezes LP, Dolabella SS, Santini A, Severino P, Capasso R, Zielinska A, Souto EB, and Jain S
- Subjects
- Animals, Cell Line, Tumor, Humans, Leukemia metabolism, Pest Control, Biological, Bacillus thuringiensis chemistry, Bacterial Proteins chemistry, Bacterial Proteins therapeutic use, Cytotoxins chemistry, Cytotoxins therapeutic use, Endotoxins chemistry, Endotoxins therapeutic use, Intranuclear Inclusion Bodies chemistry, Leukemia drug therapy
- Abstract
Bacillus thuringiensis (Bt) is a ubiquitous bacterium that produces several proteins that are toxic to different invertebrates such as insects, nematodes, mites, and also some protozoans. Among these, Cry and Cyt proteins are most explored as biopesticides for their action against agricultural pests and vectors of human diseases. In 2000, a group of researchers from Japan isolated parasporal inclusion proteins from B. thuringiensis, and reported their cytotoxic action against human leukemia. Later, other proteins with similar antitumor properties were also isolated from this bacterium and these cytotoxic proteins with specific activity against human cancer cells were named parasporins. At present, nineteen different parasporins are registered and classified in six families. These parasporins have been described to have specific in vitro antitumor activity against several cancer cell lines. The antitumor activity makes parasporins possible candidates as anticancer agents. Various research groups around the world are involved in isolating and characterizing in vitro antitumor activity of these proteins and many articles reporting such activities in detail have been published. However, there are virtually no data regarding the antitumor activity of parasporins in vivo. This review summarizes the properties of these potentially useful antitumor agents of natural origin, focusing on their in vivo activity thus also highlighting the importance of testing these proteins in animal models for a possible application in clinical oncology., (Copyright © 2021 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF